Advances in synergistic treatment of radiotherapy and chimeric antigen receptor T cell therapy for refractory / relapsed diffuse large B-cell lymphoma
10.3760/cma.j.cn113030-20220429-00154
- VernacularTitle:放疗协同CAR-T治疗在难治/复发弥漫大B细胞淋巴瘤中的研究进展
- Author:
Yun YANG
1
;
Weikai SUN
Author Information
1. 上海市同济医院放疗科，上海 200333
- Keywords:
Diffuse large B cell lymphoma;
Chimeric antigen receptor T cell;
Bridging therapy;
Radiotherapy
- From:
Chinese Journal of Radiation Oncology
2023;32(7):651-656
- CountryChina
- Language:Chinese
-
Abstract:
Chimeric antigen receptor T (CAR-T) cell therapy is one of the most significant advances in cancer treatment in the last few decades, revolutionizing the treatment paradigm for patients with refractory / recurrent diffuse large B-cell lymphoma (R/R DLBCL) and effectively improving the survival rate of these patients. However, due to the high incidence of grade III-IV side effects of CAR-T cell therapy and the fact that some patients did not obtain remission after CAR-T cell therapy or developed rapid disease progression within a short period of time, researchers are attempting to explore combined therapies, such as chemotherapy, radiotherapy and immunotherapy, to reduce the incidence of side effects and prolong the duration of persistent remission in patients. Among these options, radiotherapy in combination with CAR-T cell therapy have been proven to improve clinical prognosis. In this article, the theoretical basis of synergistic treatment of radiotherapy and CAR-T cell therapy in patients with R/R DLBCL, the safety and efficacy of radiotherapy, the sequence of radiotherapy and CAR-T cell therapy, and the dose of the target area of radiotherapy were reviewed, aiming to provide more evidence for the application and optimization of radiotherapy combined with CAR-T cell therapy for R/R DLBCL.
